|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.07.26 - 22:06
|
Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units (“RSUs”) to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on July 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
05.06.26 - 22:03
|
Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 51,300 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on June 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
|
|
26.05.26 - 22:12
|
Spyre Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
